LGC acquires Axolabs and invests in GMP manufacturing capacity for therapeutic nucleic acids

News (ZH) - Moves strengthen existing analytical and bioanalytical drug development service offering

LGC invests in new GMP analytical capability

News (ZH) - The new labs comprise additional bioanalysis and synthetic chemistry labs as well as a new GMP CMC analytical capability for batch release testing of oligonucleotide-based drug substances

LGC expands Fordham site to bolster Bioanalytical and CMC capacity

News (ZH) - LGC is expanding its Bioanalytical and CMC analytical services capacity at its site in Fordham, Cambridgeshire.

LGC accelerates the development of new medicines with extractables and leachables services

News (ZH) - LGC is helping customers to identify and quantify the compounds present in those components in direct contact with a drug product or patient

LGC launches new service for stability testing

News (ZH) - This new service enables continuous recording and monitoring of essential data on the impact of environmental factors, such as temperature and humidity, on the quality of a pharmaceutical product

LGC launches cGMP cell-based assay capability

News (ZH) - The cGMP service is an extension to the existing cell-based assay capability that LGC’s experienced team offer for biopharmaceutical development

LGC welcomes HRH The Princess Royal

News (ZH) - The Princess Royal was given a tour of LGC’s recently-expanded laboratories and met with scientists and apprentices to hear how the company’s cutting-edge analytical science supports doping and medication control in animal sports, provides assurance to athletes taking supplements, and helps develop new drugs and therapies

LGC to develop new Berlin site to expand Nucleic Acid Therapeutics capacity

News (ZH) - Site will be dedicated to medium to large scale and early to late Phase Clinical GMP manufacturing of Nucleic Acid Therapeutics